Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG802

—

f2daffc7-e2a5-585f-bc58-73b7b3086ab4

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.474
  • OXIDATIVE_PHOSPHORYLATION+0.458
  • MYC_TARGETS_V2+0.397
  • INTERFERON_GAMMA_RESPONSE+0.332
  • MYC_TARGETS_V1+0.325
  • ANGIOGENESIS+0.308
  • E2F_TARGETS+0.185
  • ALLOGRAFT_REJECTION+0.173
  • INFLAMMATORY_RESPONSE+0.129
  • DNA_REPAIR+0.128

Top 10 suppressed

  • ANDROGEN_RESPONSE-0.379
  • BILE_ACID_METABOLISM-0.254
  • WNT_BETA_CATENIN_SIGNALING-0.246
  • PANCREAS_BETA_CELLS-0.226
  • ESTROGEN_RESPONSE_LATE-0.220
  • CHOLESTEROL_HOMEOSTASIS-0.219
  • APOPTOSIS-0.214
  • XENOBIOTIC_METABOLISM-0.210
  • COAGULATION-0.203
  • HYPOXIA-0.195

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1784b2763-b9be-4b7f-84b0-f5ec6f784717
colon-landscapes@1
——0.740
2TCGA-90-A4EE-01A-11R-A24Z-07
lung-landscapes@6
—cohortSQ10.674
3MBCProject_3717_T2_RNA
breast-umap@18
—B0.673
4MNG914
mng-umap@100
——0.671
5TCGA-CQ-A4CD-01A-21R-A24Z-07
head-neck@1
——0.661
6TCGA-QK-A6IG-01A-11R-A31N-07
head-neck@1
——0.660
7C3N-00497
lung-landscapes@6
—cohortSQ10.658
8R61
bladder-landscape@3
——0.658
9SRR4195685
colon-landscapes@1
——0.653
10C3L-00927
lung-landscapes@6
—cohortSQ10.653

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.474Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.458Remibrutinib— uncovered
MYC_TARGETS_V20.397Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.332Idelalisib— uncovered
MYC_TARGETS_V10.325Inavolisib— uncovered
ANGIOGENESIS0.308Remibrutinib— uncovered
E2F_TARGETS0.185Inavolisib— uncovered
ALLOGRAFT_REJECTION0.173Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.129Idelalisib— uncovered
DNA_REPAIR0.128Idelalisib— uncovered
HEDGEHOG_SIGNALING0.112Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.095Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.091Inavolisib— uncovered
G2M_CHECKPOINT0.083Inavolisib— uncovered
APICAL_JUNCTION0.082Inavolisib— uncovered
UV_RESPONSE_UP0.078Idelalisib— uncovered
APICAL_SURFACE0.029Temsirolimus— uncovered
IL6_JAK_STAT3_SIGNALING0.023Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.017Inavolisib— uncovered
MITOTIC_SPINDLE0.013Inavolisib— uncovered